Myasthenia Gravis Pipeline
Oct 01, 2021
Exploring the Market Potential of the Upcoming Therapies for the Myasthenia Gravis
Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It occurs when the communication between nerve cells and muscles is disrupted. This impairment prevents critical muscle contractions from occurring, resulting in muscle weakness. This disease is associated with antibodies directed a...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
